

Reduction of suicidality during clozapine treatment of schizophrenia: impact on risk-benefit assessment

American Journal of Psychiatry

152, 183-190

DOI: [10.1176/ajp.152.2.183](https://doi.org/10.1176/ajp.152.2.183)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Clozapine: Efficacy and Safety. Schizophrenia Bulletin, 1995, 21, 579-591.	2.3	156
4	Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine. European Psychiatry, 1995, 10, 19s-25s.	0.1	21
6	White-blood-cell monitoring and clozapine. Lancet, The, 1995, 346, 849.	6.3	2
7	EPPIC: An Evolving System of Early Detection and Optimal Management. Schizophrenia Bulletin, 1996, 22, 305-326.	2.3	828
8	Proper psychosocial rehabilitation for stabilised patients with schizophrenia: the role of new therapies. European Neuropsychopharmacology, 1996, 6, 7-12.	0.3	11
9	Treatment-resistant schizophrenia: clinical experience with new antipsychotics. European Neuropsychopharmacology, 1996, 6, 21-25.	0.3	33
10	Adverse Effects of Antipsychotic Agents. Drugs, 1996, 51, 895-930.	4.9	81
11	Clozapine and Risperidone: Refining and Extending Their Use. Harvard Review of Psychiatry, 1996, 4, 184-199.	0.9	6
12	Cost-effectiveness of Clozapine Monitoring After the First 6 Months. Archives of General Psychiatry, 1996, 53, 954.	13.8	19
13	The experience of hope in adults with schizophrenia.. Psychiatric Rehabilitation Journal, 1996, 19, 61-65.	0.8	22
14	Schizophrenia. New England Journal of Medicine, 1996, 334, 34-42.	13.9	303
15	Consultations for research in suicidology. Archives of Suicide Research, 1997, 3, 139-151.	1.2	50
16	Recent Advances in the Pharmacotherapy of Schizophrenia. Harvard Review of Psychiatry, 1997, 4, 255-271.	0.9	33
17	Mortality in Current and Former Users of Clozapine. Epidemiology, 1997, 8, 671.	1.2	194
18	Evaluation of a Complex Case: The Value of a Drug Washout Period. American Journal of Psychiatry, 1997, 154, 1747-1750.	4.0	8
19	Olanzapine: A New Antipsychotic Agent with Efficacy in the Management of Schizophrenia. Annals of Pharmacotherapy, 1997, 31, 1325-1334.	0.9	32
20	Measuring Quality of Life in Patients with Schizophrenia. Pharmacoeconomics, 1997, 11, 32-47.	1.7	163
21	Evaluation of Treatment-Resistant Schizophrenia. Schizophrenia Bulletin, 1997, 23, 663-674.	2.3	234

#	ARTICLE	IF	CITATIONS
22	MANAGEMENT OF THE SUICIDAL PATIENT WITH SCHIZOPHRENIA. Psychiatric Clinics of North America, 1997, 20, 625-640.	0.7	25
23	Long-term effect on outcome of clozapine in chronic therapy-resistant schizophrenic patients. European Psychiatry, 1997, 12, 353s-355s.	0.1	11
24	P.2.048 Clozapine and suicide: A case report. European Neuropsychopharmacology, 1997, 7, S208-S209.	0.3	0
25	P.2.049 A double-blind, placebo-controlled study on gradual withdrawal of antiparkinsonian medication in Chinese schizophrenic patients. European Neuropsychopharmacology, 1997, 7, S209.	0.3	0
26	P.2.050 Pseudoneurotic form of schizophrenia. European Neuropsychopharmacology, 1997, 7, S209.	0.3	0
27	P.2.051 Weight gain induced by clozapine. European Neuropsychopharmacology, 1997, 7, S209.	0.3	0
28	P.2.052 A ten year follow-up of tardive dyskinesia in a nursing home population. European Neuropsychopharmacology, 1997, 7, S209-S210.	0.3	0
29	P.2.062 Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. European Neuropsychopharmacology, 1997, 7, S212-S213.	0.3	0
30	P.2.063 The efficacy of zotepine in reducing negative symptoms. European Neuropsychopharmacology, 1997, 7, S213.	0.3	1
31	P.2.064 Depressive symptomatology during clozapine treatment: Two case reports. European Neuropsychopharmacology, 1997, 7, S213.	0.3	0
32	The Management of Depressive Symptoms in Schizophrenia. , 1997, 12, 84-95.		1
33	Effects of Clozapine on Plasma Catecholamines and Relation to Treatment Response in Schizophrenia: A Within-Subject Comparison with Haloperidol. Neuropsychopharmacology, 1997, 17, 317-325.	2.8	36
34	Consultations for research in suicidology. Archives of Suicide Research, 1997, 3, 139-151.	1.2	33
35	Suicide prevention is possible: A review of recent studies. Archives of Suicide Research, 1998, 4, 329-339.	1.2	9
36	Suicide: the public health crisis of our time. Australian and New Zealand Journal of Medicine, 1998, 28, 295-300.	0.5	6
37	Assessment of suicide in schizophrenia: Development of the interview for suicide in schizophrenia. Cognitive and Behavioral Practice, 1998, 5, 139-169.	0.9	10
38	Risk factors for suicidal ideation in psychiatric patients. Social Psychiatry and Psychiatric Epidemiology, 1998, 33, 235-240.	1.6	21
39	Clozapine and body mass change. Biological Psychiatry, 1998, 43, 520-524.	0.7	65

#	ARTICLE	IF	CITATIONS
40	Depressive symptomatology during clozapine treatment: two case reports. <i>European Neuropsychopharmacology</i> , 1998, 8, 239-240.	0.3	1
41	PHARMACOECONOMICS OF THE NEW ANTIPSYCHOTICS FOR THE TREATMENT OF SCHIZOPHRENIA. <i>Psychiatric Clinics of North America</i> , 1998, 21, 181-202.	0.7	26
42	Suicide within a day of discharge - failure of risk assessment?. <i>Nordic Journal of Psychiatry</i> , 1998, 52, 15-21.	0.7	17
43	The Cost-Effectiveness of Clozapine. <i>Clinical Drug Investigation</i> , 1998, 15, 137-152.	1.1	16
44	Medical-claims databases in the design of a health-outcomes comparison of quetiapine (Seroquel [®] Seroquel is a trademark, the property of Zeneca Limited.1) and usual-care antipsychotic medication. <i>Schizophrenia Research</i> , 1998, 32, 51-58.	1.1	11
45	Features and Toxicokinetics of Clozapine in Overdose. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 92-97.	1.0	41
46	Suicide and Suicidal Behaviours: Implications for Mental Health Services. <i>Canadian Journal of Psychiatry</i> , 1998, 43, 785-791.	0.9	11
47	Suicide as a complication of schizophrenia. <i>Irish Journal of Psychological Medicine</i> , 1998, 15, 24-25.	0.7	3
48	Antipsykotikas indflydelse på suicidaladfærd blandt skizofrene patienter. <i>Nordic Journal of Psychiatry</i> , 1998, 51, 39-47.	0.7	0
49	Hospital Days in Clozapine-Treated Patients. <i>Canadian Journal of Psychiatry</i> , 1998, 43, 945-948.	0.9	21
50	Maintenance doses for clozapine. <i>Psychiatric Bulletin</i> , 1998, 22, 12-14.	0.3	6
51	9. Managing schizophrenia in the community. <i>Medical Journal of Australia</i> , 1998, 168, 186-191.	0.8	2
52	Analysis of the initial treatment phase in first-episode psychosis. <i>British Journal of Psychiatry</i> , 1998, 172, 71-76.	1.7	76
53	Which atypical antipsychotic?. <i>British Journal of Psychiatry</i> , 1998, 172, 106-109.	1.7	49
54	Schizophrenia: Improving Outcome. <i>Harvard Review of Psychiatry</i> , 1999, 6, 229-240.	0.9	38
55	Enforcing treatment with clozapine: survey of views and practice. <i>Psychiatric Bulletin</i> , 1999, 23, 342-345.	0.3	13
56	Treatment of schizophrenia in low-income countries. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 321-325.	1.0	22
59	Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinical Trial. <i>Pharmacopsychiatry</i> , 1999, 32, 148-153.	1.7	76

#	ARTICLE	IF	CITATIONS
60	Dopamine receptors and schizophrenia: contribution of molecular genetics and clinical neuropsychology. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 197-227.	1.0	14
61	Clozapine associated with decreased suicidality in bipolar disorder: a case report. <i>Bipolar Disorders</i> , 1999, 1, 123-124.	1.1	13
62	Gender Differences in Living Skills and Global Assessment of Functioning Among Outpatients with Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 1999, 33, 226-231.	1.3	16
63	Circadian rhythm of white blood cells during clozapine treatment. <i>Psychopharmacology</i> , 1999, 144, 301-302.	1.5	31
64	The Role of Serotonin in Antipsychotic Drug Action. <i>Neuropsychopharmacology</i> , 1999, 21, 106S-115S.	2.8	615
65	Active monitoring of 12760 clozapine recipients in the UK and Ireland. <i>British Journal of Psychiatry</i> , 1999, 175, 576-580.	1.7	270
66	Hypotension associated with clozapine after cardiopulmonary bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1999, 13, 597-599.	0.6	19
68	Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. <i>Biological Psychiatry</i> , 1999, 46, 73-77.	0.7	116
69	Pharmacologic treatment of schizophrenia. <i>Biological Psychiatry</i> , 1999, 46, 1396-1408.	0.7	134
70	Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. <i>Schizophrenia Research</i> , 1999, 35, 41-50.	1.1	239
71	Managing aggression in schizophrenia. <i>Journal of the American Psychiatric Nurses Association</i> , 1999, 5, S9-S16.	0.4	2
72	A Comparative Review of New Antipsychotics. <i>Canadian Journal of Psychiatry</i> , 1999, 44, 235-244.	0.9	98
73	Suicide Risk in Schizophrenia: An Analysis of 17 Consecutive Suicides. <i>Schizophrenia Bulletin</i> , 1999, 25, 533-542.	2.3	63
74	Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. <i>American Journal of Psychiatry</i> , 1999, 156, 88-93.	4.0	73
75	An Assessment of Clinical Practice of Clozapine Therapy for Veterans. <i>Psychiatric Services</i> , 2000, 51, 669-671.	1.1	12
76	Youth suicidal behavior: Assessment and intervention. <i>Journal of Clinical Psychology</i> , 2000, 56, 1131-1152.	1.0	62
77	A South Australian Coronial Inquiry Into Suicide and Homicide. <i>Australasian Psychiatry</i> , 2000, 8, 142-146.	0.4	2
78	Weight gain from novel antipsychotic drugs: need for action. <i>General Hospital Psychiatry</i> , 2000, 22, 224-235.	1.2	128

#	ARTICLE	IF	CITATIONS
79	Treatment refractory schizophrenia. , 2000, 71, 373-384.		120
80	The symptom of depression in schizophrenia and its management. <i>Advances in Psychiatric Treatment</i> , 2000, 6, 169-177.	0.6	78
81	The new antipsychotics - some pharmacological aspects of their problems and potential. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 181-185.	0.9	4
82	Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials. <i>Archives of General Psychiatry</i> , 2000, 57, 311.	13.8	460
83	Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents. <i>American Journal of Psychiatry</i> , 2000, 157, 1379-1389.	4.0	373
84	A 52-Year-Old Suicidal Man. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2693.	3.8	6
85	Rational Suicide, Hastened Death, and Self-Destructive Behaviors. <i>Counseling Psychologist</i> , 2000, 28, 540-550.	0.8	7
86	Clozapine for schizophrenia: Clinical effect, financial considerations, and quality requirements. <i>Nordic Journal of Psychiatry</i> , 2000, 54, 143-148.	0.7	4
87	Antipsychotic drugs and risk of homicide. <i>Lancet, The</i> , 2000, 355, 2073.	6.3	3
88	A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 41-46.	1.2	34
89	Schizophrenia in the Elderly. <i>CNS Drugs</i> , 2000, 13, 103-115.	2.7	20
90	Role of Newer Atypical Antipsychotics in the Management of Treatment- Resistant Schizophrenia. <i>CNS Drugs</i> , 2000, 13, 409-420.	2.7	10
91	Reducing Suicide Risk in Schizophrenia. <i>CNS Drugs</i> , 2000, 14, 355-365.	2.7	23
92	State of the Art of Drug Treatment of Schizophrenia and the Future Position of the Novel/Atypical Antipsychotics. <i>World Journal of Biological Psychiatry</i> , 2000, 1, 204-214.	1.3	41
93	Opportunities and challenges presented by the new generation antipsychotics. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 53-61.	1.2	8
94	Psychiatric Aspects of Suicidal Behaviour: Schizophrenia. , 0, , 121-134.		18
95	Dexamethasone suppression test and suicide attempts in schizophrenic patients. <i>European Psychiatry</i> , 2001, 16, 428-431.	0.1	31
96	Olanzapine. <i>Drugs</i> , 2001, 61, 111-161.	4.9	180

#	ARTICLE	IF	CITATIONS
97	Suicide and schizophrenia. <i>Journal of Psychopharmacology</i> , 2001, 15, 127-135.	2.0	303
98	Management of treatment resistance in schizophrenia. <i>Biological Psychiatry</i> , 2001, 50, 898-911.	0.7	305
99	Insights into the structure and function of 5-HT ₂ family serotonin receptors reveal novel strategies for therapeutic target development. <i>Expert Opinion on Therapeutic Targets</i> , 2001, 5, 685-695.	1.5	33
100	Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling. <i>Journal of Medical Economics</i> , 2001, 4, 179-192.	1.0	5
101	Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia. <i>Annual Review of Medicine</i> , 2001, 52, 503-517.	5.0	293
102	Determining the optimal dose of haloperidol in first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2001, 15, 251-255.	2.0	44
103	Pharmacological Treatment of Schizophrenia: A Review. , 2001, , 75-146.		3
104	Impact of Clozapine on Completed Suicide. <i>American Journal of Psychiatry</i> , 2001, 158, 931-937.	4.0	96
105	Diagnosis and Treatment of Mood Disorders That Co-occur With Schizophrenia. <i>Psychiatric Services</i> , 2001, 52, 911-919.	1.1	18
106	5-HT _{2C} receptor antagonists: Potential in schizophrenia. <i>Drug Development Research</i> , 2001, 54, 88-94.	1.4	25
107	Suicidal behavior in schizophrenia and schizoaffective disorder. <i>Clinical Neuroscience Research</i> , 2001, 1, 345-350.	0.8	13
108	Psychopharmacologic strategies for the prevention of suicidal behavior in bipolar patients. <i>Clinical Neuroscience Research</i> , 2001, 1, 387-393.	0.8	3
109	Outcomes of suicidal behaviors. <i>Clinical Neuroscience Research</i> , 2001, 1, 394-404.	0.8	2
110	Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration Database. <i>American Journal of Psychiatry</i> , 2001, 158, 1449-1454.	4.0	127
111	Evaluation of suicide prevention: a European approach. <i>International Review of Psychiatry</i> , 2002, 14, 34-41.	1.4	12
112	Estimating the Costs and Benefits of New Drug Therapies: Atypical Antipsychotic Drugs for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2002, 28, 619-635.	2.3	26
113	A Case Control Study on Psychopharmacotherapy before Suicide Committed by 61 Psychiatric Inpatients. <i>Pharmacopsychiatry</i> , 2002, 35, 37-43.	1.7	24
114	Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. <i>International Clinical Psychopharmacology</i> , 2002, 17, 249-261.	0.9	16

#	ARTICLE	IF	CITATIONS
115	A Current Perspective of Suicide and Attempted Suicide. <i>Annals of Internal Medicine</i> , 2002, 136, 302.	2.0	416
116	Anxiety and Schizophrenia. , 0, , 163-179.		1
117	Transcranial Magnetic Stimulation for Panic. <i>American Journal of Psychiatry</i> , 2002, 159, 315-a-316.	4.0	39
118	Clozapine-Induced Stuttering and Seizures. <i>American Journal of Psychiatry</i> , 2002, 159, 315-315.	4.0	55
119	Re: Schizophrenia, Suicide, and Blood Count during Treatment with Clozapine. <i>Canadian Journal of Psychiatry</i> , 2002, 47, 977-977.	0.9	5
120	The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2002, 28, 5-16.	2.3	140
121	II The usefulness of the second-generation antipsychotic medications. <i>Current Opinion in Psychiatry</i> , 2002, 15, S7-S16.	3.1	4
122	Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders. <i>Biological Psychiatry</i> , 2002, 52, 631-654.	0.7	18
123	Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital. <i>Schizophrenia Research</i> , 2002, 53, 1-6.	1.1	54
124	Circumstances of suicide among individuals with schizophrenia. <i>Schizophrenia Research</i> , 2002, 58, 253-261.	1.1	53
125	Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2. <i>European Neuropsychopharmacology</i> , 2002, 12, 261-268.	0.3	26
126	Reduction of Suicidality in Patients with Schizophrenia Receiving Clozapine. <i>Clinical Drug Investigation</i> , 2002, 22, 341-346.	1.1	10
127	New Pyridobenzodiazepine Derivatives:Â Modifications of the Basic Side Chain Differentially Modulate Binding to Dopamine (D4.2, D2L) and Serotonin (5-HT2A) Receptors. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5136-5149.	2.9	22
128	ValoraciÃ³n del paciente suicida. Riesgos y prevenciÃ³n. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2002, 9, 168-175.	0.0	0
129	Schizophrenia and Other Psychotic Disorders: Therapeutic Armamentarium. , 0, , 685-700.		0
130	Re: Billsbury and Others. More on the Phenomenology of Perfectionismâ€™Incompleteness. <i>Canadian Journal of Psychiatry</i> , 2002, 47, 977-978.	0.9	8
131	Suicide in secure psychiatric facilities. <i>Advances in Psychiatric Treatment</i> , 2002, 8, 408-417.	0.6	12
132	The clinical epidemiology of suicide in schizophrenia. , 2002, , 288-316.		2

#	ARTICLE	IF	CITATIONS
134	Mortality of patients with mood disorders: follow-up over 34 years. <i>Journal of Affective Disorders</i> , 2002, 68, 167-181.	2.0	795
135	Suicidality in schizophrenia: A review of the evidence for risk factors and treatment options. <i>Current Psychiatry Reports</i> , 2002, 4, 279-283.	2.1	78
136	Is clozapine cost-effective?. <i>European Journal of Health Economics</i> , 2002, 3, s104-s113.	1.4	3
137	Early Intervention in Psychosis: An Overdue Reform. <i>Australian and New Zealand Journal of Psychiatry</i> , 2003, 37, 393-398.	1.3	104
138	Summary Australian and New Zealand Clinical Practice Guideline for the Management of Adult Deliberate Self-Harm (2003). <i>Australasian Psychiatry</i> , 2003, 11, 150-155.	0.4	39
139	Neurobiology of suicidal behaviour. <i>Nature Reviews Neuroscience</i> , 2003, 4, 819-828.	4.9	1,086
140	Atypical antipsychotics and suicide in mood and anxiety disorders. <i>Bipolar Disorders</i> , 2003, 5, 48-52.	1.1	88
141	Evidence-based treatment for schizophrenia. <i>Psychiatric Clinics of North America</i> , 2003, 26, 939-954.	0.7	40
142	Detection and management of comorbidity in patients with schizophrenia. <i>Psychiatric Clinics of North America</i> , 2003, 26, 115-139.	0.7	125
143	Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses. <i>Drugs</i> , 2003, 63, 2265-2283.	4.9	48
144	Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. <i>Schizophrenia Research</i> , 2003, 59, 59-66.	1.1	43
145	Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. <i>Schizophrenia Research</i> , 2003, 60, 47-55.	1.1	100
146	Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. <i>Schizophrenia Research</i> , 2003, 60, 71-80.	1.1	195
147	H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs. <i>Neuropsychopharmacology</i> , 2003, 28, 519-526.	2.8	694
148	Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. <i>Biological Psychiatry</i> , 2003, 54, 444-452.	0.7	95
149	Clozapine. <i>CNS Drugs</i> , 2003, 17, 273-280.	2.7	38
150	Clozapine in prevention of suicide in patients with schizophrenia: profile report. <i>Drugs and Therapy Perspectives</i> , 2003, 19, 5-6.	0.3	0
151	Suicide Risk in Placebo vs Active Treatment in Placebo-Controlled Trials for Schizophrenia. <i>Archives of General Psychiatry</i> , 2003, 60, 365.	13.8	38

#	ARTICLE	IF	CITATIONS
152	Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia. <i>Journal of Psychopharmacology</i> , 2003, 17, 210-215.	2.0	53
153	Clozapine Treatment for Suicidality in Schizophrenia–International Suicide Prevention Trial (InterSePT)–. <i>Archives of General Psychiatry</i> , 2003, 60, 82.	13.8	1,200
154	Diabetes Mellitus Associated with Atypical Anti-Psychotic Medications. <i>Diabetes Technology and Therapeutics</i> , 2003, 5, 669-683.	2.4	20
155	Do Psychosocial and Pharmacological Interventions Reduce Suicide in Schizophrenia and Schizophrenia Spectrum Disorders?. <i>Archives of Suicide Research</i> , 2003, 7, 353-374.	1.2	18
156	Clinical Outcome in a Randomized 1-Year Trial of Clozapine Versus Treatment as Usual for Patients With Treatment-Resistant Illness and a History of Mania. <i>Focus (American Psychiatric Publishing)</i> , 2003, 1, 37-43.	0.4	87
157	Treatment-Resistant Schizophrenia. , 0, , 489-516.		13
158	N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13674-13679.	3.3	269
159	Suicide and Schizophrenia: A Review of Literature for the Decade (1990-1999) and Implications for Mental Health Nursing. <i>Issues in Mental Health Nursing</i> , 2003, 24, 27-43.	0.6	48
160	Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents. <i>Neuropsychopharmacology</i> , 2003, 28, 1-13.	2.8	132
161	Antipsychotic drugs in bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 277-284.	1.0	23
162	The evaluation of suicide prevention activities: State of the art. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 156-165.	1.3	40
163	Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. <i>British Journal of Psychiatry</i> , 2003, 182, 505-508.	1.7	53
164	Clozapine Treatment for Suicidality in Schizophrenia–Correction. <i>Archives of General Psychiatry</i> , 2003, 60, 735.	13.8	3
165	Pharmacological Treatment of Schizophrenia: A Review. , 2003, , 75-152.		4
166	Preventing suicide. <i>British Journal of Psychiatry</i> , 2003, 182, 365-365.	1.7	0
167	Preventing suicide. <i>British Journal of Psychiatry</i> , 2003, 182, 366-366.	1.7	7
168	Cost-effectiveness of an atypical conventional antipsychotic in South Africa: An economic evaluation of quetiapine versus haloperidol in the treatment of patients partially responsive to previous antipsychotics. <i>South African Journal of Psychiatry</i> , 2004, 10, 7.	0.2	2
169	New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability–Are Patients Better Off?. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 297-302.	0.9	69

#	ARTICLE	IF	CITATIONS
170	Antisucide Properties of Psychotropic Drugs: A Critical Review. <i>Harvard Review of Psychiatry</i> , 2004, 12, 14-41.	0.9	37
171	The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003. <i>Schizophrenia Bulletin</i> , 2004, 30, 193-217.	2.3	538
172	The International Suicide Prevention Trial (InterSePT): Rationale and Design of a Trial Comparing the Relative Ability of Clozapine and Olanzapine To Reduce Suicidal Behavior in Schizophrenia and Schizoaffective Patients. <i>Schizophrenia Bulletin</i> , 2004, 30, 577-586.	2.3	31
173	Suicide and awareness of illness in schizophrenia: An overview. <i>Bulletin of the Menninger Clinic</i> , 2004, 68, 297-318.	0.3	46
174	Suicide and suicide attempts in adolescent-onset psychotic disorders. <i>Nordic Journal of Psychiatry</i> , 2004, 58, 115-123.	0.7	45
175	Is clozapine antisuicidal?. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 187-190.	1.4	26
176	Investigation of M1/M4 Muscarinic Receptors in the Anterior Cingulate Cortex in Schizophrenia, Bipolar Disorder, and Major Depression Disorder. <i>Neuropsychopharmacology</i> , 2004, 29, 619-625.	2.8	143
177	Suicidal Behavior in Schizophrenia and Schizoaffective Disorder: Examining the Role of Depression. <i>Suicide and Life-Threatening Behavior</i> , 2004, 34, 66-76.	0.9	52
178	Suicide Attempts in an African Schizophrenia Population: An Assessment of Demographic Risk Factors. <i>Suicide and Life-Threatening Behavior</i> , 2004, 34, 320-327.	0.9	11
179	Toward a New Prevention of Suicide in Schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 201-210.	1.3	30
180	Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia. <i>CNS Drugs</i> , 2004, 18, 877-893.	2.7	113
183	LETTER TO THE EDITOR“MAKING SENSE OF NURSES' ROLE IN THE PREVENTION OF SUICIDE IN SCHIZOPHRENIA. <i>Issues in Mental Health Nursing</i> , 2004, 25, 5-7.	0.6	8
184	Atypical antipsychotic drugs and stress. <i>Handbook of Behavioral Neuroscience</i> , 2005, 15, 301-313.	0.0	4
185	Pharmacogenetic Testing in the Clinical Management of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 427-434.	0.7	49
186	MedikamentÄrse Behandlung der SuizidalitÄt. <i>Verhaltenstherapie</i> , 2005, 15, 29-37.	0.3	8
187	Suicide risk: structured professional judgement. <i>Advances in Psychiatric Treatment</i> , 2005, 11, 84-91.	0.6	44
188	Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. <i>International Clinical Psychopharmacology</i> , 2005, 20, 183-198.	0.9	75
189	Changes in mental disorder distribution among suicide attempters in mid-west area of Kanagawa. <i>Psychiatry and Clinical Neurosciences</i> , 2005, 59, 113-118.	1.0	7

#	ARTICLE	IF	CITATIONS
190	Lack of an association between 5-HT6 receptor gene polymorphisms and suicide victims. <i>Psychiatry and Clinical Neurosciences</i> , 2005, 59, 345-349.	1.0	16
191	Priorities and standards in pharmacogenetic research. <i>Nature Genetics</i> , 2005, 37, 671-681.	9.4	135
192	Suicidal disorders: A nosological entity per se?. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2005, 133C, 3-7.	0.7	31
193	Continuing clozapine treatment despite neutropenia. <i>European Journal of Clinical Pharmacology</i> , 2005, 60, 759-764.	0.8	41
194	Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 83-93.	1.8	53
195	SuizidprÄvention: Vorgehensweisen und Wirksamkeit. <i>Verhaltenstherapie</i> , 2005, 15, 12-19.	0.3	1
196	Fatal poisoning with antipsychotic drugs, England and Wales 1993-2002. <i>Journal of Psychopharmacology</i> , 2005, 19, 667-674.	2.0	20
197	Suicide in 406 Mood-Disorder Patients With and Without Long-Term Medication: A 40 to 44 Years' Follow-Up. <i>Archives of Suicide Research</i> , 2005, 9, 279-300.	1.2	289
198	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 132-191.	1.3	242
199	Pharmacotherapy of Suicidal Behavior in Bipolar Disorder. <i>Archives of Suicide Research</i> , 2005, 9, 237-250.	1.2	12
200	Suicidal risk during treatment with clozapine: a meta-analysis. <i>Schizophrenia Research</i> , 2005, 73, 139-145.	1.1	246
201	Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 247-263.	1.3	54
202	Challenging behaviour in Mental Health Services: Combining psychological perspectives. <i>Journal of Mental Health</i> , 2006, 15, 475-490.	1.0	13
203	NK3 receptor antagonists for the treatment of schizophrenia. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 555-560.	0.5	17
204	Emotional processing in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2006, 11, 250-271.	0.7	65
205	Suicide et schizophrÄnie: Ävaluation du risque et prÄvention. <i>Annales Medico-Psychologiques</i> , 2006, 164, 165-175.	0.2	6
206	Diretrizes da FederaÃ§Ã£o Mundial das Sociedades de Psiquiatria BiolÃ³gica para o tratamento biolÃ³gico da esquizofrenia. Parte 1: tratamento agudo. <i>Revista De Psiquiatria Clinica</i> , 2006, 33, 7-64.	0.6	9
207	Dislipidemias e antipsicÃ³ticos atÃ³picos. <i>Jornal Brasileiro De Psiquiatria</i> , 2006, 55, 296-307.	0.2	5

#	ARTICLE	IF	CITATIONS
208	The overlapping of the spectra suicide. , 0, , 224-247.		0
209	Suicidal behaviour and cognitive problem solving therapy: theory, application and review. Irish Journal of Psychological Medicine, 2006, 23, 29-32.	0.7	4
210	Treatment of Suicidality in Schizophrenia. Annals of the New York Academy of Sciences, 2001, 932, 44-60.	1.8	96
211	cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects. Pharmacogenomics Journal, 2006, 6, 131-140.	0.9	26
212	A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. European Journal of Health Economics, 2006, 7, 165-172.	1.4	19
213	The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia, 2006, 49, 2930-2938.	2.9	21
214	Depression in Schizophrenia, Can it be Treated? A Review of the Evidence. Current Psychiatry Reviews, 2006, 2, 371-379.	0.9	2
215	Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring. Annals of Pharmacotherapy, 2006, 40, 683-688.	0.9	95
216	Meta-Analysis of Aggression and/or Hostility-Related Events in Children and Adolescents Treated with Fluoxetine Compared with Placebo. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 713-718.	0.7	7
218	ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders. American Journal of Health-System Pharmacy, 2007, 64, 863-876.	0.5	12
219	Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. International Clinical Psychopharmacology, 2007, 22, 249-267.	0.9	46
220	Developing psychological perspectives of suicidal behaviour and risk in people with a diagnosis of schizophrenia: We know they kill themselves but do we understand why?. Clinical Psychology Review, 2007, 27, 511-536.	6.0	91
221	When Should Clozapine Be Initiated in Schizophrenia?. CNS Drugs, 2007, 21, 267-278.	2.7	23
222	Despite safety concerns, clozapine has a unique profile of clinical benefits in patients with treatment-resistant schizophrenia or schizophrenia-associated suicidality. Drugs and Therapy Perspectives, 2007, 23, 9-13.	0.3	0
223	Transcultural differences in suicide attempters: Analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder. Schizophrenia Research, 2007, 89, 140-146.	1.1	21
225	Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Preference and Adherence, 2007, Volume 1, 19-27.	0.8	13
226	Suicide risk in schizophrenia: learning from the past to change the future. Annals of General Psychiatry, 2007, 6, 10.	1.2	235
227	Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiology and Drug Safety, 2008, 17, 686-696.	0.9	69

#	ARTICLE	IF	CITATIONS
228	New and old antipsychotics: what "effectiveness" trials tell us. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 443-446.	0.2	1
230	Pimavanserin tartrate: a 5-HT _{2A} inverse agonist with potential for treating various neuropsychiatric disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 3251-3259.	0.9	74
231	The InterSePT suicide scale for prediction of imminent suicidal behaviors. <i>Psychiatry Research</i> , 2008, 161, 87-96.	1.7	18
232	Suicide in Psychiatric Patients: Case-Control Study in Singapore. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 509-519.	1.3	30
233	Does Acute Treatment with Sedatives/Hypnotics for Anxiety in Depressed Patients Affect Suicide Risk? A Literature Review. <i>Annals of Clinical Psychiatry</i> , 2008, 20, 157-169.	0.6	50
234	Assessment and treatment of suicide risk in schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 51-74.	1.4	36
235	Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders. <i>Neuropsychopharmacology</i> , 2009, 34, 204-212.	2.8	16
236	The role of psychopharmacology in suicide prevention. <i>Epidemiologia E Psichiatria Sociale</i> , 2009, 18, 172-178.	1.0	31
237	A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. <i>Schizophrenia Research</i> , 2009, 107, 13-21.	1.1	34
238	Management of Schizophrenia with Suicide Risk. <i>Psychiatric Clinics of North America</i> , 2009, 32, 863-883.	0.7	27
239	The Treatment of Adolescent Suicide Attempters Study (TASA): Predictors of Suicidal Events in an Open Treatment Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 987-996.	0.3	219
240	Suicidal Behavior in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2009, 197, 147-153.	0.5	42
241	Suicide prevention in first-episode psychosis. , 2009, , 257-282.		2
242	Care of the Suicidal Patient. , 2010, , 541-554.		0
243	Antipsicóticos atípicos e comportamento suicida em pacientes esquizofrênicos ou esquizoafetivos. <i>Revista De Psiquiatria Clinica</i> , 2010, 37, 228-232.	0.6	1
244	Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder. <i>Pharmaceuticals</i> , 2010, 3, 3522-3542.	1.7	6
245	Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 27-37.	0.5	14
246	An Approach to the Patient in Crisis: Assessments of the Risk of Suicide and Violence. <i>Medical Clinics of North America</i> , 2010, 94, 1089-1102.	1.1	8

#	ARTICLE	IF	CITATIONS
247	The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. <i>Schizophrenia Bulletin</i> , 2010, 36, 71-93.	2.3	822
248	The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2010, 51, 165-170.	1.5	18
249	A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2010, 177, 286-293.	1.7	24
250	The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia11The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMEA or one of its committees or working parties or the BfArM.. <i>European Neuropsychopharmacology</i> , 2010, 20, 139-145.	0.3	11
251	Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. <i>European Neuropsychopharmacology</i> , 2010, 20, 829-838.	0.3	19
252	Assessment of Therapy-Resistant Schizophrenia. <i>Advances in Biological Psychiatry</i> , 2010, , 9-32.	0.2	2
253	Role of Clozapine in Treatment-Resistant Schizophrenia. <i>Advances in Biological Psychiatry</i> , 2010, , 114-128.	0.2	16
254	Estrategias farmacolÃ³gicas de potenciaciÃ³n en esquizofrenia refractaria a clozapina: mÃ¡s alla de la resistencia. <i>Psiquiatria Biologica</i> , 2010, 17, 96-101.	0.0	3
255	Managing Suicide Risk in Patients with Schizophrenia. <i>CNS Drugs</i> , 2011, 25, 129-143.	2.7	103
256	Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2011, 25, 567-620.	2.0	332
257	The Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy. <i>Neuropsychopharmacology</i> , 2011, 36, 638-651.	2.8	63
258	Elucidating biological risk factors in suicide: Role of protein kinase A. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 831-841.	2.5	29
259	Elderly Patients with Schizophrenia and Depression: Diagnosis and Treatment. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011, 4, 239-250.	1.4	32
261	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i>Molecular Psychiatry</i> , 2011, 16, 76-85.	4.1	141
262	Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression. <i>EPMA Journal</i> , 2011, 2, 391-402.	3.3	6
263	Suicidal behavior in the older patient with schizophrenia. <i>Aging Health</i> , 2011, 7, 379-393.	0.3	17
264	Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia. <i>Neuropsychopharmacology</i> , 2011, 36, 616-626.	2.8	103
265	Clozapine Safety, 35 Years Later. <i>Current Drug Safety</i> , 2011, 6, 164-184.	0.3	35

#	ARTICLE	IF	CITATIONS
266	Schizophrenia and Suicide. <i>Current Approaches in Psychiatry</i> , 2011, , 611.	0.2	2
267	Suicide: An Indian perspective. <i>Indian Journal of Psychiatry</i> , 2012, 54, 304.	0.4	167
268	A systematic review of the evidence of clozapine's anti-aggressive effects. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1351-1371.	1.0	175
269	Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 807-811.	0.7	20
270	Typical and Atypical Antipsychotic Drugs Increase Extracellular Histamine Levels in the Rat Medial Prefrontal Cortex: Contribution of Histamine H1 Receptor Blockade. <i>Frontiers in Psychiatry</i> , 2012, 3, 49.	1.3	11
271	The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 194-216.	0.4	7
272	Qualitative content of auditory hallucinations and suicidal behavior in schizophrenia. <i>Schizophrenia Research</i> , 2012, 134, 298-299.	1.1	4
273	Olanzapine discontinuation for schizophrenia. <i>The Cochrane Library</i> , 0, , .	1.5	1
274	Depression and schizophrenia. <i>Advances in Psychiatric Treatment</i> , 2012, 18, 280-288.	0.6	9
275	Clozapine. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 6, 177-185.	1.4	16
276	Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: Results from a 12-week, flexible dose study using raters masked to antipsychotic choice. <i>Asian Journal of Psychiatry</i> , 2013, 6, 200-207.	0.9	21
277	The role of ethnicity in treatment refractory schizophrenia. <i>Comprehensive Psychiatry</i> , 2013, 54, 167-172.	1.5	18
278	Psychopharmacologic Treatment of Psychosis in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2013, 22, 727-744.	1.0	21
279	Medication and suicide risk in schizophrenia: A nested case-control study. <i>Schizophrenia Research</i> , 2013, 150, 416-420.	1.1	37
280	Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics. <i>Journal of Affective Disorders</i> , 2013, 145, 77-82.	2.0	35
281	Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up. <i>Schizophrenia Research</i> , 2013, 150, 274-280.	1.1	61
282	Update on Typical and Atypical Antipsychotic Drugs. <i>Annual Review of Medicine</i> , 2013, 64, 393-406.	5.0	337
283	Schizophrenia and depression. <i>Medical Journal of Australia</i> , 2013, 199, S36-9.	0.8	34

#	ARTICLE	IF	CITATIONS
286	Risk factors for suicide in schizophrenia: systematic review and clinical recommendations. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 418-426.	2.2	123
287	An association between autumn birth and clozapine treatment in patients with schizophrenia: A population-based analysis. <i>Nordic Journal of Psychiatry</i> , 2014, 68, 428-432.	0.7	8
288	Clozaphobia: Fear of Prescribers of Clozapine for Treatment of Schizophrenia. <i>Journal of Microbiology and Biotechnology</i> , 2014, 24, 295-301.	0.9	21
289	The Treatment of Pediatric Suicidal Behavior. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 66-83.	0.7	1
290	Clozapine oral suspension (Versaclozâ„¢): a guide to its use in the USA. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 193-199.	0.3	0
291	Schizophrenia and Suicide: Treatment Optimization. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 149-162.	0.7	2
292	The Contributions of Lithium and Clozapine for the Prophylaxis and Treatment of Suicidal Behavior. <i>Advances in Biological Psychiatry</i> , 2016, , 145-160.	0.2	7
294	Revisiting loxapine: a systematic review. <i>Annals of General Psychiatry</i> , 2015, 14, 15.	1.2	58
295	Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data. <i>Schizophrenia Research</i> , 2015, 161, 429-433.	1.1	22
296	Clozapine and GABA transmission in schizophrenia disease models. , 2015, 150, 47-80.		38
297	Ketamine and suicidal ideation in depression: Jumping the gun?. <i>Pharmacological Research</i> , 2015, 99, 23-35.	3.1	38
298	Suicidal ideation in depressed postpartum women: Associations with childhood trauma, sleep disturbance and anxiety. <i>Journal of Psychiatric Research</i> , 2015, 66-67, 95-104.	1.5	81
299	Memories reactivated under ketamine are subsequently stronger: A potential pre-clinical behavioral model of psychosis. <i>Schizophrenia Research</i> , 2015, 164, 227-233.	1.1	31
300	Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. <i>Journal of Affective Disorders</i> , 2015, 183, 159-165.	2.0	58
301	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 142-170.	1.3	106
302	Pharmacogenetics of quetiapine in healthy volunteers. <i>International Clinical Psychopharmacology</i> , 2015, 30, 82-88.	0.9	23
303	Clozapine for treatment-resistant bipolar disorder: a systematic review. <i>Bipolar Disorders</i> , 2015, 17, 235-247.	1.1	105
304	Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1700.	1.8	46

#	ARTICLE	IF	CITATIONS
306	Clinical Psychopharmacology. , 2016, , 707-780.		2
307	Clozapina: una revisi3n. Psiquiatria Biologica, 2016, 23, 87-92.	0.0	0
308	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. Molecular Neuropsychiatry, 2016, 2, 185-197.	3.0	14
310	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine. Human Psychopharmacology, 2016, 31, 121-134.	0.7	19
311	Possible natural therapeutics against schizophrenia and its acute and treatment resistant forms: a review. Journal of Biologically Active Products From Nature, 2016, 6, 1-24.	0.1	3
312	Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study. EBioMedicine, 2016, 5, 125-134.	2.7	71
314	Pharmacogenetic Studies of Suicide: Potential Relevance of Main Polymorphic CYPs and ABCB1. , 2016, , 415-433.		0
315	Understanding Suicide. , 2016, , .		4
316	A two-hit model of suicide-trait-related behaviors in the context of a schizophrenia-like phenotype: Distinct effects of lithium chloride and clozapine. Physiology and Behavior, 2016, 156, 48-58.	1.0	17
317	Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial. American Journal of Psychiatry, 2016, 173, 491-498.	4.0	233
318	Why not clozapine for the patient with schizophrenia at risk of suicide?. Asian Journal of Psychiatry, 2017, 26, 6-7.	0.9	1
319	Preventing Suicide in Forensic Settings. Journal of Correctional Health Care, 2017, 23, 383-397.	0.2	8
320	The association between season of birth, age at onset, and clozapine use in schizophrenia. Acta Psychiatrica Scandinavica, 2017, 136, 445-454.	2.2	14
321	The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study. CNS Drugs, 2017, 31, 75-85.	2.7	30
322	ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research, 2018, 105, 23-32.	1.5	71
323	Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. Frontiers in Neuroscience, 2018, 12, 203.	1.4	47
324	The androgen model of suicide completion. Progress in Neurobiology, 2019, 172, 84-103.	2.8	38
325	Does Compulsory Admission Prevent Inpatient Suicide Among Patients with Schizophrenia? A Nationwide Cohort Study in Taiwan. Suicide and Life-Threatening Behavior, 2019, 49, 966-979.	0.9	4

#	ARTICLE	IF	CITATIONS
326	Clozapine augmentation strategies – a systematic meta-review of available evidence. Treatment options for clozapine resistance. <i>Journal of Psychopharmacology</i> , 2019, 33, 423-435.	2.0	52
327	Critical appraisal of major depression with suicidal ideation. <i>Annals of General Psychiatry</i> , 2019, 18, 7.	1.2	66
328	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	2.0	259
329	ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 2114-2132.	0.5	4
330	Neurocognitive Functioning and Suicidal Behavior in Violent Offenders with Schizophrenia Spectrum Disorders. <i>Diagnostics</i> , 2020, 10, 1091.	1.3	5
331	Effectiveness of Antipsychotics in Reducing Suicidal Ideation: Possible Physiologic Mechanisms. <i>Healthcare (Switzerland)</i> , 2021, 9, 389.	1.0	3
332	Use of Medications in Suicide Prevention. , 2021, , 149-170.		0
333	Translating Interventional Neuroscience to Suicide: It's About Time. <i>Biological Psychiatry</i> , 2021, 89, 1073-1083.	0.7	10
334	Psychosis and Hopelessness Mediate the Relationship Between Reduced Sleep and Suicidal Ideation in Schizophrenia Spectrum Disorders. <i>Archives of Suicide Research</i> , 2022, 26, 1862-1879.	1.2	3
336	Clozapine in patients with schizoaffective disorder: A systematic review. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2021, 14, 148-156.	0.2	3
337	Pharmacotherapy of Suicidal Ideation and Behaviour. , 0, , 487-502.		11
338	Prediction of Suicide and Attempted Suicide. , 0, , 585-595.		33
339	Prevention of Suicide in Psychiatric Patients. , 0, , 615-630.		8
341	Depression and Schizophrenia. , 0, , 142-167.		47
342	Pharmakotherapie schizophrener Störungen. , 2000, , 209-241.		4
345	Sleep and suicide in psychiatric patients. <i>Annals of Clinical Psychiatry</i> , 2001, 13, 93-101.	0.6	39
346	The metabolism of atypical antipsychotic drugs: an update. <i>Annals of Clinical Psychiatry</i> , 1999, 11, 145-58.	0.6	14
347	Risk factors for suicidal behaviour: translating knowledge into practice. , 2005, , 161-182.		3

#	ARTICLE	IF	CITATIONS
349	Treatment of Schizoaffective Disorder and Schizophrenia With Mood Symptoms. American Journal of Psychiatry, 1999, 156, 1138-1148.	4.0	118
350	Focus on Clozapine. Current Medical Research and Opinion, 2001, 17, 223-229.	0.9	37
351	Treatment-refractory schizophrenia. Dialogues in Clinical Neuroscience, 2004, 6, 61-70.	1.8	27
352	Clozapine. Clinical Schizophrenia and Related Psychoses, 2012, 6, 134-144.	1.4	183
353	A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. Clinical Schizophrenia and Related Psychoses, 2016, , .	1.4	4
354	Predictors of Response to Clozapine. Psychiatric Annals, 1996, 26, 385-389.	0.1	12
355	Management of Depression in Schizophrenia. Psychiatric Annals, 2000, 30, 13-19.	0.1	6
356	Clozapine: Treatment of Mood Symptoms. Psychiatric Annals, 2002, 32, 722-729.	0.1	2
357	Managing Depression in: Schizophrenia. Psychiatric Annals, 2005, 35, 60-69.	0.1	6
358	Impulsivity, Aggression, and Suicide Risk in Patients with Schizophrenia. Psychiatric Annals, 2013, 43, 458-462.	0.1	2
359	Clozapine: Current perspective. Indian Journal of Psychiatry, 2007, 49, 271.	0.4	12
360	Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. Indian Journal of Medical Research, 2016, 144, 697.	0.4	11
361	Suicide risk and prevention in patients with schizophrenia. Suicidologi, 2015, 14, .	0.0	1
362	Fostering the use of clozapine in the severely mentally ill through academic detailing. Mental Health Clinician, 2011, 1, 94-98.	0.5	4
363	Effects of somatic treatments on suicidal ideation and completed suicides. Brain and Behavior, 2021, 11, e2381.	1.0	11
364	Prueba de supresi3n con dexametasona e intentos de suicidio en pacientes esquizofr3nicos. European Psychiatry (Ed Espa3ola), 2002, 9, 128-131.	0.0	0
365	The Suicidal Patient. , 2008, , 733-745.		3
366	Management of the Suicidal Patient. , 0, , 2478-2490.		1

#	ARTICLE	IF	CITATIONS
367	Efficacy of Novel Antipsychotic Drugs in Treatment-Refractory Schizophrenia. Handbook of Experimental Pharmacology, 2010, , 333-357.	0.9	1
368	Current Understanding of Violence and Aggression: Assessment and Treatment. Journal of Psychosocial Nursing and Mental Health Services, 1998, 36, 18-24.	0.3	13
369	Levels of Recovery From Psychotic Disorders Chart. Journal of Psychosocial Nursing and Mental Health Services, 1998, 36, 31-37.	0.3	2
370	Der Einsatz von Neuroleptika bei depressiven Erkrankungen. , 1999, , 149-165.		0
371	Clozapine: between efficacy and safety. Psychiatria I Psychologia Kliniczna, 2015, 15, 57-60.	0.3	1
372	Schizophrenia and Suicide. , 2017, , .		11
373	Suicide in Schizophrenia Spectrum Disorders: A Review of Sociodemographic and Clinical Correlates. Indian Journal of Private Psychiatry, 2018, 12, 20-26.	0.1	1
375	Health-related quality of life in patients treated with atypical antipsychotics. Revista Brasileira De Psiquiatria, 2020, 42, 599-607.	0.9	2
376	Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study. Journal of Psychiatry and Neuroscience, 2000, 25, 347-52.	1.4	21
377	Are suicide terrorists suicidal? A critical assessment of the evidence. Innovations in Clinical Neuroscience, 2014, 11, 81-92.	0.1	7
378	The risk of suicide after clozapine discontinuation: Cause for concern. Annals of Clinical Psychiatry, 2015, 27, 253-6.	0.6	16
379	Activity-State Dependent Reversal of Ketamine-Induced Resting State EEG Effects by Clozapine and Naltrexone in the Freely Moving Rat. Frontiers in Psychiatry, 2022, 13, 737295.	1.3	4
380	Catalytic Reaction Model of Suicide. Frontiers in Psychiatry, 2022, 13, 817224.	1.3	5
381	The Importance of Suicide Risk Formulation in Schizophrenia. Frontiers in Psychiatry, 2021, 12, 779684.	1.3	14
384	Clinical Outcome in a Randomized 1-Year Trial of Clozapine Versus Treatment as Usual for Patients With Treatment-Resistant Illness and a History of Mania. American Journal of Psychiatry, 1999, 156, 1164-1169.	4.0	188
387	The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinsonâ€™s Disease Psychosis. , 2019, , 10-43.		0
388	Assessment and Management of Suicidal Risk. , 2023, , 1-32.		0
389	Prevention of suicide by clozapine in mental disorders: systematic review. European Neuropsychopharmacology, 2023, 69, 4-23.	0.3	14

#	ARTICLE	IF	CITATIONS
390	The Protective Effect of Clozapine on Suicide. Journal of Clinical Psychiatry, 2023, 84, .	1.1	1